February 7, 2023
You are here:  Home  >  Health Care & Life Science  >  Current Article

Amgen sues competitor to block generic version of Sensipar


Thousand Oaks biotech powerhouse Amgen filed a complaint in North Carolina District Court against a competitor seeking to make a generic of its drug Sensipar, used by patients with chronic kidney disease. Accord Healthcare, a Durham, N.C.-based subsidiary of Indian company Intas Pharmaceuticals, allegedly alerted Amgen that it had filed an Abbreviated New Drug Application…


    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.